⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
668 postmenopausal women with HR+/HER2- recurrent or metastatic breast cancer randomized to ribociclib 600mg + letrozole vs placebo + letrozole. PFS significantly longer with ribociclib (HR 0.56, 95% CI 0.43–0.72, p=3.29×10⁻⁶). Higher myelosuppression in ribociclib group. Funded by Novartis Pharmaceuticals (MONALEESA-2, NCT01958021).
Coeff. authors = avg(0.85, 0.70) = 0.77
Coeff. editorial = avg(1.00, 0.90) = 0.95
min(0.77, 0.95) = 0.77← lowest dominates
Alert signal : eoc → Coefficient forced to 0.3
Expression of Concern published
Final coefficient : 0.77
Final score = 46.5/52.8 × 0.77 × 100 = 68/100
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Piccart-Gebhart MJ — 2005 · The New England journal of medicine
Contrasted resultsOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson M — 2017 · The New England Journal of Medicine
Contrasted resultsImproved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB — 2011 · The New England journal of medicine
Contrasted resultsPembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck M — 2016 · The New England Journal of Medicine
Contrasted results5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally adva…
Gianni L — 2016 · The Lancet Oncology